79 results about "Tumor size" patented technology

This invention relates to the destruction of pathological volumes or target structures such as cancerous tumors or aberrant functional target tissue volumes by direct thermal destruction. In the case of a tumor, the destruction is implemented in one embodiment of the invention by percutaneous insertion of one or more radiofrequency probes into the tumor and raising the temperature of the tumor volume by connection of these probes to a radiofrequency generator outside of the body so that the isotherm of tissue destruction enshrouds the tumor. The ablation isotherm may be predetermined and graded by proper choice of electrode geometry and radiofrequency (rf) power applied to the electrode with or without temperature monitoring of the ablation process. Preplanning of the rf electrode insertion can be done by imaging of the tumor by various imaging modalities and selecting the appropriate electrode tip size and temperature to satisfactorily destroy the tumor volume. Computation of the correct three-dimensional position of the electrode may be done as part of the method, and the planning and control of the process may be done using graphic displays of the imaging data and the rf ablation parameters. Specific electrode geometries with adjustable tip lengths are included in the invention to optimize the electrodes to the predetermined image tumor size.

The presence of tumor nodules in organs often results in serious clinical manifestations and the permeation by cancer cells of sheaths surrounding organs often produces clinical manifestations of pleural effusion, ascites or cerebral edema. The present invention addresses this problem by providing a method for treating tumors comprising (a) intratumoral administration of a superantigen and/or (b) intrathecal or intracavitary administration of a superantigen directly into the sheath. Intratumoral superantigen results in significant and sustained reduction of the tumor size. Intrathecal administration produces significant sustained reduction of the fluid accumulation associated with clinical improvement and prolonged survival. Useful superantigen compositions for intrathecal and intratumoral injection include tumoricidally effective homologues, fragments and fusion proteins of native superantigens. Also disclosed is combined therapy that includes intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs.

Methods of regressing or inhibiting a tumor in a subject by administering an agent capable of blocking, inhibiting, or ameliorating vascular endothelial growth factor (VEGF)-mediated activity to a subject in need thereof such that the tumor is regressed or inhibited. The method of the invention results in a reduction of tumor size and inhibition of tumor metastases. This method is particularly useful for patients suffering from bulky, metastatic cancers.

Method and system for the detection of interval change in medical images. Three dimensional images, such as previous and current section images in CT scans, are obtained. An anatomic feature, such as the lungs, is used to select sections containing lung by a gray-level thresholding technique. The section correspondence between the current and previous scans is determined automatically. The initial registration of the corresponding sections in the two scans is achieved by a rotation correction and a cross-correlation technique. A more accurate registration between the corresponding current and previous section images is achieved by local matching. A nonlinear warping process which is also based on the cross-correlation technique is applied to the previous image to yield a warped image after the matching. The final subtracted section images were derived by subtracting of the previous section images from the corresponding current section images. Interval changes such as a change in tumor size and a newly developed pleural effusion are enhanced significantly.

The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size. In contrast to classic Sags, the egc superantigens induced minimal toxicity, are rarely associated with the presence of preformed antibodies and are used as a plurality with a broad T cell Vβ profile. Useful egc superantigen compositions for parenteral administration native egc enterotoxins, homologues, fragments and fusion proteins of native egc enterotoxins capable of activating a broad spectrum of T cells expressing T cell receptor/α motifs. T cell survival-enhancing cytokines IL-7, Il-15, Il-23 are used. together with parenteral egc SE therapy. Also disclosed is combined therapy that includes parenteral, intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs or (iii) radiation therapy or (iv) anti-angiogenic and tyrosine kinase inhibitors.

A method and device that can deliver a time-varying electric field non-invasively inside of biological tissue and/or biological fluid such as blood and/or lymph and/or synovial fluid and/or interstitial fluid and/or other fluids in-vivo and with magnitudes that do not cause a tolerable amount of neural motor and sensory action potential generation and frequency components below the megahertz range by means of the placement of more than one electrode on the skin with or without some intermediate biological, synthetic, or natural agent or substance between the electrode and the skin and/or by induction by means of a time-varying magnetic field or both with the novel purpose of activation and/or potentiation and/or normalization and/or regulation and/or stimulation and/or signaling and/or increase and/or regulation of the alertness and/or self tuning of the immune system or any of its parts or components directly or indirectly, locally and/or globally with the purpose of pathogen load reduction and/or reduction of the disease symptoms and/or clinical improvement and/or tumor size reduction and/or malignancy reduction or amelioration and/or improvement of the effects of an autoimmune disorder or any other related condition that could be treated or remised by its effects.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×10⁶ human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg/gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg/gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention relates to a breast cancer recurrent risk assessment 21 gene detection primer and application thereof. The breast cancer recurrent risk assessment 21 gene detection primer comprises a nucleotide sequence as shown in an SEQ ID NO.: 1 to 42, and belongs to the technical field of molecular detection. The detection primer provided by the invention utilizes the advantage of fluorescent quantitation, and adopts fluorescent quantitation polymerase chain reaction to carry out amplification detection on 21 genes for breast cancer recurrent risk assessment, so that whether clinical measurements such as adjuvant chemotherapy are needed or not is considered. A kit provides a PCR (Polymerase Chain Reaction) amplification primer sequence of the 21 genes for breast cancer recurrent risk assessment, and the primer is applicable to detecting ER positive patients, HER2 negative patients, axillary node negative patients, moderately and poorly differentiated patients with the tumor size being 0.6 to 1.0cm and adverse prognostic factors, or patients with the tumor size is larger than 1cm, has the advantages of high sensitivity and specificity, stability, promptness, convenience in operation and the like, can well meet the clinical application of breast cancer recurrent risk assessment, and can be beneficial for reducing invalid medication administration, improving medication administration accuracy, and reducing financial burdens of the patients.

The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.

The invention relates to a tumor targeting hyperthermia method based on metal particles or thermochemical reaction of the compounds thereof. First, the tumor size and position are determined by a B-ultrasound, a CT or an nuclear magnetic resonance image; reactant to be used is determined according to the tumor size and position and is put into the a conveying cavity at the rear part of the stent of a syringe; under the guide of the imaging equipment, the skin that is in the position of the tumor is punctured, and the syringe is inserted into the targeting tissue of the tumor, then the reactant is injected inside the targeting tissue of the tumor; the reactant is micro nanometer metal and the compound thereof and can generate chemical heat to lead tumor tissue necrosis so as to reach the purpose of tumor tissue thermotherapy after combining with the DNA molecules of the human body. The tumor hyperthermia method is easy to carry out conformal treatment to the tumor of complex shape; the reactant is injected under room temperature, therefore the surrounding health tissue cannot be burnt during injecting; besides, the invention has the advantages of fast heatingup response speed, good treatment effect, low cost, convenient operation, etc.

An object of the present invention is to find a new oncolytic virus and to utilize it for treatment of cancers. The present invention relates to a pharmaceutical composition for treatment of cancers containing Sindbis virus as an active ingredient, a method for treatment of cancers, which comprises administering a therapeutically effective amount of Sindbis virus to a mammal having cancers, a method for identifying cancers, which comprises introducing Sindbis virus into an animal, thereby detecting a Sindbis virus protein or Sindbis virus RNA in vital tissues of the above animal, a method of identifying cancers, which comprises introducing into an animal Sindbis virus having a reporter gene incorporated therein, thereby, detecting the product of said reporter gene in vital tissues of said animal, and a method of identifying cancers, which comprises detecting a increase in antibody titer to the Sindbis virus protein or the product of the reporter gene in the aforementioned animals. It is confirmed that Sindbis virus has cytopathic effects upon various cancer cell lines in vitro, and that reduction in tumor size or disappearance of tumor takes place in vivo. Therefore, Sindbis virus is effective for treatment of cancers. In addition, Sindbis virus shows selective proliferation in a tumor, and is effective for identification or diagnosis for cancers within the living body.

The invention discloses a breast cancer metastasis assessment kit. The breast cancer metastasis assessment kit comprises specific fluorescent quantitative PCR detection primer pairs of total 11 target genes including BIRC5, DHCR7, UBE2C, AZGP1, IL6ST, MGP, RBBP8, STC2, CALM2, OAZ1 and RPL37A and preferably further comprises Taqman probes of the 11 target genes. By detecting the expression levels of the 11 target genes and combining pathological information such as the lymph node status and the tumor size of a breast cancer patient, the relapse and far-end metastasis risks of the breast cancer patient in 10 years can be assessed, the patient can adopt corresponding treatment measures, and excessive treatment is avoided. The kit is easy and convenient to operate, easy to interpret and low in requirement on instruments; in addition, due to the fact that a totally-closed mode is adopted in the whole PCR process, the cross contamination possibility is avoided, and then a result is more precise.

Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and/or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cellsto levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non- metastatic cancerous, pre-cancerous, or neoplastic cells in vivo.; The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.

The invention discloses a radioactive particle stent used for radiotherapy in a cavity tumor. The stent comprises a stent body 1 formed by weaving an alloy tube wire 3 and provided with an opening along a long axis, and radioactive particles 2, wherein the radioactive particles 2 are arranged in the alloy tube wire 3 with the opening. The stent is simple in structure, simple and convenient to prepare and convenient to use, can be prepared according to different specifications and types, is suitable for different tumor sizes, and realizes conformal therapy of the cavity tumor, so that the curative effect is improved and the injury to normal tissues is reduced. The radioactive particles are firmly clamped or bonded to different positions of the alloy tube wire with the opening, so that the falling probability of the radioactive particles is reduced. The radiation shielding of the wall of the alloy tube wire to the radioactive particles is reduced; the radioactivity utilization efficiencyis improved; and the cost is reduced.

The invention belongs to the field of medicines, and particularly relates to a medicine composition and application thereof in preparation of medicines for treating brain glioma. The medicine composition is prepared from the following medicinal active ingredients: elemene and pomalidomide in an optimal proportion of (0.003-100):1, and a further optimal proportion of (0.01-50):1. Massive pharmacological experiments prove that elemene and pomalidomide have remarkable synthetic effects in the field of brain glioma treatment, and can be used for remarkably reducing the tumor size and weight and prolonging the surviving period. The medicine composition has the advantages of exact curative effect and small toxic and side effects when being used for treating brain glioma, and has good medical application prospects.

The invention discloses compositions and methods for increasing chemotherapeutic specificity to endocrine dependent cancers, and reducing systemic toxicity, through administration of endocrine hormones in conjunction with administration of phase specific chemotherapeutics. The invention also discloses why prior art phase specific chemotherapeutic regimens fail to achieve high cure rates for cancer. The failure relates to the Gompertzian acceleration, or reduction in cancer cell cycle time, induced by the chemotherapeutic reduction of tumor size, which in turn results in the cancer's lack of phase synchronicity to subsequent administrations of the phase specific chemotherapeutic(s). The invention discloses how to avoid this failure in endocrine dependent cancers by using endocrine blockers between chemotherapeutic administrations to halt the cancer cells from passing the S-Phase and then using endocrine hormones to restart and accelerate S-Phase progression in conjunction with administration of appropriate phase specific chemotherapeutic(s).

The invention provides an external medicine for treating cervical carcinoma, which is prepared from the following active ingredients: 3-6g of Galla Chinensis, 3-6g of Brucea javanica fruit, 3-6g of aconitum carmichaeli rootlet, 13-17g of prunus mume charcoal, 7.5-10.5g of indigo naturalis, 2-4g of borneol, 4.5-7.5g of benzoin, 4.5-7.5g of bezoar, 11.5-12.5g of scolopendra subspinipes, 8.5-10.5g of scorpion, 5.8-10.5g of daemonorops draco, 4-8g of radix arnebiae and 5.5-6.5g of toad. The neck of uterus is exposed in the visual field by use of a vaginal dilator, and the medicinal powder is dipped with a cotton swab and smeared on the canceration part on the neck of uterus, and the Chinese medicine is applied once a day. After the external medicine is used for three days, the sizes of the tumors of some patients start shrinking; after continuous application of the medicine for 1-3 months, among all of 36 patients with cervical carcinoma, tumor disappearance is found in 22 patients (61.1%), tumor size shrinkage is found in 12 patients (33.3%), and no change of tumor size is found in 2 patients (5.6%), and the total effective rate is 94.4%.

The present invention provides compositions and methods of using curcumin or curcumin derivatives or analogs to activate the pro-apoptotic enzymes caspase-3/7 in cancer cells. The present invention also provides formulations of curcumin or derivatives or analogs with increased solubility or improved bioavailability. The formulations may be administered to a subject such that high concentrations of therapeutically effective curcumin compounds resuit in the subject's bloodstream. The invention thus involves the use of curcumin or curcumin derivatives or analogs to diminish cancer cell growth, decrease tumor size, prevent tumor formation, and Curcumin Carrier to reduce or prevent cancer or tumor cell invasion or metastasis into a tissue, e.g., into the nervous System and especially the brain, of a subject. The instant invention may be used prophylactically to prevent tumor formation or metastasis, as a monotherapy to treat existing tumors, after surgery to prevent recurrence of tumors or in conjunction with conventional cancer therapies to improve patient prognosis and reduce side-effects.

The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.

The present invention provides a method for testing the efficiency of delivering an inhibitory polynucleotide to a target cell or tissue. The invention also provides a method for testing efficiency of delivering and efficacy for an effect on tumor size of an inhibitory polynucleotide against a target gene.